Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1995-04-07
1998-05-05
Degen, Nancy
Drug, bio-affecting and body treating compositions
Lymphokine
514 12, 514 21, 530351, 536 64, A61K 3819, C07H 15252, C07K 14525
Patent
active
057470235
ABSTRACT:
Methods and compositions are provided which include use of lymphotoxin (LT) and one or more other anti-cancer therapies for treating cancer in vivo or ex vivo. LT can be employed, for instance, with chemotherapy or radiation therapy to provide improved anti-cancer therapy.
REFERENCES:
patent: 4405601 (1983-09-01), McEntire et al.
patent: 4828830 (1989-05-01), Wong
patent: 4861587 (1989-08-01), Urbaschek et al.
patent: 4920196 (1990-04-01), Aggarwal
patent: 4959457 (1990-09-01), Bringman
patent: 5133960 (1992-07-01), Schlick et al.
patent: 5277903 (1994-01-01), Schlick et al.
Van Moorselaar et al. "Combined Effects of Tumor Necrosis Factor .alpha. & Radiation in the Treatment of Renal Cell Carcinoma Grown on Radon Spheroids" Anticancer Res 10 1769-1774 1990.
Regenass et al. "Antitumor Effects of TNF in Combination w/Chemotherapeutic Agents" Int. J. Canc. 39 266-273 1987.
Buckley et al., "Schedule-Dependent Enhanced Lethality with Combined Administration of Actinomycin D and Tumor Necrosis Factor in Mice" J. Biological Response Modifiers 8:287-296 (1989).
Mashiba et al.,"Augmentation of Antitumor Effect in Combined Use of Lymphotoxin and Antitumor Drug on MethA Tumors" Immunobiology 175(1-2):98 (1987).
Matsunaga et al., "Amplification of Cytotoxic Effect of Antitumor Drugs by Combined Use of Lymphotoxin" Chemical Abstracts (abstract only) 104(1):27 (1986).
Matsunaga et al., "Augmentation of in vitro cytotoxicity and in vivo tumor-inhibition by combined use of lymphotoxin-containing supernatants and antitumor drugs" Cancer Letters 20:21-28 (1983).
Mikami et al, "In vivo Effects of Recombinant Human Lymphotoxin on Human Medulloblastoma Xenograft: Enhancement of Antitumor Activity of Etoposide" Biotherapy 8:7-17 (1995).
Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium, Dicke et al., University of Texas M.D. Anderson Hospital (1987).
Remington's Pharmaceutical Sciences, Oslo et al., 16th edition, Mack Publishing Co. (1980).
Aggarwal, "Comparative Analysis of the Structure and Function of TNF-.alpha. and TNF-.beta." Tumor Necrosis Factors: Structure, Function and Mechanism of Action, Aggarwal and Vicek, eds., pp. 61-78 (1992).
Aggarwal et al., "Human Tumor Necrosis Factor" Journal of Biological Chemistry 260(4):2345-2354 (1985).
Aggarwal et al., "Lymphotoxin and Tumor Necrosis Factor: Qualitative and Quantitative Differences in Their Receptors and Signal Transduction in Various Cell Types" Cytokines and Lipocortins in Inflammation and Differentiation, Wiley-Liss, Inc. pp. 375-384 (1990).
Benjamin et al., "Human B-Cell TNF-.beta. Microheterogeneity" Lymphokine and Cytokine Research 11(1):45-54 (1992).
Carswell et al., "An endotoxin-induced serum factor that causes necrosis of tumors" Proc. Natl. Acad. Sci. 72(9):3666-3670 (1975).
Cludts, "Cloning and Characterization of the Tandemly Arranged Bovine Lymphotoxin and Tumour Necrosis Factor-Alpha Genes" Cytokine 5(4):336-341 (Jul. 1993).
Dalmau et al., "Interleukin-1 and Tumor Necrosis Factor-Alpha as Radio-and Chemoprotectors of Bone Marrow" Bone Marrow Transplantation 12:551-563 (1993).
Fiers, "Precursor Structures and Structure-Function Analysis of TNF and Lymphotoxin" Tumor Necrosis Factors, Aggarwal and Vilcek, eds., pp. 79-92 (1992).
Fukushima et al., "N-Linked Sugar Chain Structure of Recombinant Human Lymphotoxin Produced by CHO Cells: The Functional Role of Carbohydrate as to Its Lectin-like Character and Clearance Velocity" Archives of Biochemistry & Biophysics 304(1):144-153 (1993).
Funahashi et al, "Tumour Growth Inhibition in Mice by Glycosylated Recombinant Human Lymphotoxin: Analysis of Tumor-Regional mononuclear Cells Involved with Its Action" Br. J. Cancer 67:447-455 (1993).
Funahashi et al., "Usefulness of Glycosylated Recombinant Human Lymphotoxin for Growth Inhibition of Human and Murine Solid Tumors and Experimental Metastasis in Mice" Journal of Immunotherapy 10:28-38 (1991).
Goeddel et al., "Tumor Necrosis Factors: Gene Structure and Biological Activities" Cold Spring Harbor Symposia on Quantitative Biology LI:597-609 (1986).
Goh, "Tumour Necrosis Factors in Clinical Practice" Ann. Acad. Med. Singapore 19:235-239 (1990).
Gray et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity" Nature 312:721-724 (1984).
Hallahan et al. Intl. J. Radiation Oncology, Biology, Physics (Abstract No. 94) 27 (Suppl. 1, No. 184) (1993).
Hallahan et al., "The Effects of Cytokines on Tumor Cells" Important Advances in Oncology pp. 75-76 (1993).
Haranaka et al., "Antitumor Activity of Murine Tumor Necrosis Factor (TNF) Against Transplanted Murine Tumors and Heterotransplanted Human Tumors in Nude Mice" Int. J. Cancer 34:263-267 (1984).
Hussein et al., "Protection from Chemotherapy-Induced Alopecia in a Rat Model" Science 249:1564-1566 (1990).
Jeffes et al., "Human Alpha Lymphotoxin (LT): Studies Examining the Mechanism(s) of LT-Induced Inflammation and Tumor Destruction In Vivo" Lymphokine Research 6(2):141-149 (1987).
Kawatsu et al., "The Pharmacokinetic Pattern of Glycosylated Human Recombinant Lymphotoxin (LT) in Rats after Intravenous Administration" J. Pharmacobio-Dyn. 13:549-557 (1990).
Kawatsu et al., "Synergistic Antitumor Effect of Glycosylated Recombinant Human Lymphotoxin with Human Interferon-.gamma. Lymphotoxin-Sensitive Human Tumor" Journal of Interferon Research 10:519-529 (1990).
Kircheis et al., "Differences in the Biological Activity of TNF.alpha. and TNF.beta. Correlate with Their Different Abilities for Binding to the Target Cells" Eur. Cytokine Netw. 3(4):381-390 (1992).
Kofler et al., "Size Heterogeneity of Human Lymphotoxin Is Due to O-Linked Glycosylation" Lymphokine and Cytokine Research 11(1):9-14 (1992).
Li et al., "Cloning and Expression of Murine Lymphotoxin cDNA" J. of Immunology 138(12):4496-4501 (Jun. 15, 1987).
Lipoldova et al., "Expression of the Gene for Tumor Necrosis Factor-.beta. but Not for Tumor Necrosis Factor-.alpha. is Impaired in Tumor-Bearing Mice" Cellular Immunology 152:234-239 (1993).
Locksley et al., "Tumor Necrosis Factors .alpha. and .beta. Differ in Their Capacities to Generate Interleukin 1 Release from Human Endothelial Cells" J. of Immunology 139(6):1891-1895 (Sep. 15, 1987).
Matsuyama et al., "Nucleotide Sequence of a cDNA Encoding Human Tumor Necrosis Factor .beta. from B Lymphoblastoid Cell RPMI 1788" FEBS Letters 302(2):141-144 (May 1992).
Mikami et al., "Antitumor Effect of Recombinant Human Lymphotoxin on a Tumor Line of Human Malignant Glioma" Hiroshima J. Med. Sci. 38(3):103-107 (Sep. 1989).
Mordenti et al., "Interspecies Scaling of Clearance and Volume Distribution Data for Five Therapeutic Proteins" Pharmaceutical Research 8(11):1351-1359 (1991).
Nakata et al., "Combined Effect of PT-050 (Recombinant Human TNF) and Antitumor Drugs on Syngeneic Murine Tumors" Jap. J. Cancer Chemo. (English translation) 13:3186-3193 (1986).
Neta, "Radioprotection with Cytokines--Learning from Nature to Cope with Radiation Damage" Cancer Cells 3:391-396 (1991).
Neta et al., "Comparison of the In Vivo effects of rIL-1 and rTNF in radioprotection, induction of CSF and of acute phase reactants" Fed. Proc. (Abstract) 46(4):1200 (1987).
Neta et al., "Cytokines in therapy of radiation injury" Blood 72(3):1093-1095 (Sep. 1988).
Neta et al., "Interdependence of the radioprotective effects of human recombinant interleukin 1.alpha., tumor necrosis factor .alpha., granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor", J. Immunol., 40(1):108-111 (1988).
Neta et al., "Interleukin 1 is a Radioprotector" J. Immunol. 136:2483-2485 (1986).
Nishiguchi et al., "Tumor Necrosis Factor as an Adjunct to Fractionated Radiotherapy in the Treatment of Murine Tumors" Int. J. Radiation Oncology Biol. Phys. 18:555-558 (1990).
Palladino, M. et al., "Characterization of the antitumor activities of human tumor necrosis factor-.alpha. and the comparison with other cytokines: induction of tumor-specific immunity" J. Immunol. 138:4023-4032 (1987).
Paul et al., "Lymphotoxin" Ann. Rev
Goeddel David V.
Wong Grace H. W.
Degen Nancy
Genentech Inc.
Marschang Diane L.
LandOfFree
Cancer therapy using lymphotoxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer therapy using lymphotoxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer therapy using lymphotoxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-51044